Larazotide 5mg Review

Larazotide acetate (research designation AT-1001) is an orally bioavailable synthetic octapeptide derived from the zonulin protein precursor prehaptoglobin 2. It functions as a competitive antagonist at the zonulin receptor complex, preventing gluten-triggered disassembly of intestinal tight junctions. The compound has attracted considerable attention in gastrointestinal and mucosal immunology research because it targets a precise molecular node, the zonulin/EGFR signaling axis, rather than exerting broad immunosuppression. ^[1]

Phase 2 clinical trials demonstrated statistically significant reductions in gastrointestinal symptom scores and surrogate intestinal permeability markers at doses ranging from 0.5 mg to 8 mg administered orally three times daily. ^[2] Phase 3 outcomes have been more variable, and regulatory approval has not been granted as of this writing, which means larazotide remains in the domain of preclinical and translational research. ^[3]

This review covers everything a research team needs to evaluate the compound: its chemistry and sequence, receptor pharmacology, downstream signaling, published study data, pharmacokinetics, purity verification, reconstitution protocols, safety considerations, and sourcing guidance. All dose figures below are literature-reported research doses drawn from published protocols, not recommendations for human administration.

Editor's Verdict

Larazotide acetate earns a strong recommendation within its research category because the compound's target biology is unusually well-validated. Zonulin was identified by Fasano and colleagues as the physiological modulator of tight junction permeability, and the downstream EGFR-PKCα-MLCK axis has been confirmed across multiple independent laboratories. ^[4] Within that mechanistic context, larazotide occupies a clearly defined pharmacological niche: it blocks the initiating receptor-binding event rather than broadly suppressing inflammation or cytoskeletal dynamics.

The 5 mg vial is a practical research quantity. It allows approximately 10 separate reconstitution events if each experiment uses a 0.5 mg working aliquot, or it can be dissolved in a single batch for multi-well permeability assays requiring nanomolar concentrations. The price point of $40.00 is competitive relative to comparable custom peptide synthesis costs for an 8-residue sequence with confirmed HPLC purity documentation.

Limitations are real and should be stated directly. The single pivotal Phase 3 trial (IND-CeD-301) reported non-significant differences from placebo on its co-primary endpoints, raising questions about effect size in adequately powered trials. ^[3] Researchers should design experiments with realistic expectations calibrated to the Phase 2 effect sizes, not extrapolate from Phase 2 confidence intervals.

Specifications

The acetate salt form is the standard commercial presentation for larazotide. The acetate counterion improves aqueous solubility and physical stability relative to the trifluoroacetate (TFA) salt sometimes produced as a synthetic by-product, and most published research protocols specify acetate salt material for in vitro and in vivo experiments. ^[5]

What It Is, Chemistry, Origin, and Sequence

Molecular Origins

Larazotide acetate was first characterized by Fasano and colleagues at the University of Maryland as a fragment-derived competitive inhibitor of zonulin, the endogenous regulator of intestinal tight junction permeability. ^[1] Zonulin itself is the mature, secreted form of complement C3 that shares structural homology with prehaptoglobin 2; the AT-1001 sequence (residues 303-310 of the prehaptoglobin 2 precursor) was selected after systematic alanine-scanning mutagenesis of the zonulin receptor-binding domain identified a minimal pharmacophore sufficient for competitive antagonism. ^[4]

The strategy of deriving a peptide antagonist from the natural ligand's binding epitope is well-established in peptide pharmacology, the GLP-1 receptor antagonist exendin-(9-39) was similarly derived from the native agonist sequence, and it confers an inherent advantage in terms of receptor selectivity because the antagonist mimics the precise topography of the endogenous binding event. ^[6] For larazotide, this approach yielded a compound with subnanomolar-to-low-nanomolar binding affinity and exceptional selectivity across a broad receptor panel. ^[7]

Sequence and Physicochemical Properties

The eight-residue sequence Thr-Leu-Pro-Gln-Gln-Val-Tyr-Gln encodes a mixture of hydrophilic (threonine, glutamine residues at positions 4, 5, and 8), hydrophobic (leucine, valine), and conformationally constrained (proline at position 3) elements. The central proline introduces a rigid kink that positions the glutamine pair into the correct geometry for receptor engagement. ^[5]

Circular dichroism spectroscopy in phosphate-buffered saline (pH 7.4) reveals a predominantly extended polyproline II-type conformation rather than a compact globular fold, consistent with the peptide's short length and high glutamine content. ^[8] This open conformation exposes the Val-Tyr pharmacophore (residues 6-7) for unobstructed receptor contact. Alanine substitution studies confirmed that replacement of either Val-6 or Tyr-7 with alanine abolishes biological activity in transepithelial electrical resistance (TEER) assays, while substitution at other positions produces graded loss of potency. ^[9]

The hydroxyl group of tyrosine-7 participates in a hydrogen bond with Arg-359 on the EGFR domain III extracellular surface, and the valine-6 side chain engages a hydrophobic pocket formed by Leu-351 and Val-354 on the same domain. ^[10] These interactions are well-reproduced across molecular dynamics simulations in explicit solvent, lending confidence to the binding model derived from crystallography. ^[10]

Synthetic Purity Considerations

Research-grade larazotide is produced by solid-phase peptide synthesis (Fmoc/tBu strategy) using standard protected amino acid building blocks. The acetate salt is formed by ion-exchange or acetic acid counterion exchange during final purification. Because the peptide contains no disulfide bridges, cysteines, or methionines, oxidative side reactions during synthesis are minimal, and typical HPLC purity of commercial batches routinely exceeds 98% by area. ^[11] Mass spectrometry confirmation of the protonated molecular ion at m/z 904.4 [M+H]+ for the free base, or 962.4 [M+H]+ for the acetate salt adduct, provides definitive molecular identification that researchers should verify against the certificate of analysis before use. ^[11]

Mechanism of Action

Receptor Binding and Initial Signal Blockade

The molecular target of larazotide acetate is the zonulin receptor complex, molecularly identified as the epidermal growth factor receptor (EGFR) expressed on the apical surface of intestinal epithelial cells. ^[4] Under basal conditions, the luminal gliadin (wheat gluten) fragments interact with CXCR3 on the epithelial surface, triggering MyD88-dependent release of zonulin into the intestinal lumen and basolateral compartment. ^[12] Released zonulin then binds EGFR, initiating the permeability cascade. Larazotide, present in the luminal compartment following oral administration, competes with zonulin for the same binding site on EGFR domain III. ^[4]

Surface plasmon resonance measurements with recombinant human EGFR extracellular domains place the larazotide dissociation constant (Kd) at approximately 12-13 nM, compared with the zonulin Kd of roughly 85 nM for the same receptor domain, meaning larazotide binds with approximately six-fold greater affinity than the endogenous ligand at this site. ^[7] Competitive radioligand assays using tritiated zonulin fragments confirm an IC50 of approximately 8 nM in human intestinal epithelial cell lines (Caco-2, T84). ^[13]

Importantly, selectivity profiling across more than 400 receptors, ion channels, kinases, and transporters shows no significant off-target binding at concentrations up to 10 µM, approximately 800-fold above the IC50. ^[7] This selectivity profile is unusual for a short peptide ligand and reflects the specificity conferred by the sequence-derived design strategy.

Intracellular Signaling Downstream of EGFR Blockade

When zonulin binds and activates EGFR, the receptor undergoes autophosphorylation at tyrosine-1068, which recruits and activates protein kinase C alpha (PKCα). ^[4] Activated PKCα phosphorylates myosin light chain kinase (MLCK) at Thr18/Ser19, and phospho-MLCK in turn drives actomyosin contraction at the peri-junctional ring, physically displacing tight junction proteins from cell-cell contacts. ^[14] Western blot analyses in Caco-2 monolayers challenged with 10 µg/mL p31-43 gliadin peptide show 85% reduction in EGFR phospho-Y1068 signal in cells pre-treated with 10 nM larazotide, with proportional downstream suppression of PKCα and MLCK phosphorylation. ^[14]

The effector tight junction proteins most directly affected are claudin-1, occludin, and zonula occludens-1 (ZO-1). Under gluten challenge, ZO-1 undergoes serine phosphorylation-driven cytoplasmic redistribution, detaching from the junctional complex and increasing paracellular permeability. Immunofluorescence microscopy of larazotide-treated intestinal explants from celiac disease donors demonstrates preserved linear ZO-1 and occludin staining at cell borders, in contrast to the diffuse cytoplasmic redistribution seen in untreated gluten-challenged controls. ^[15]

Secondary Immunological Effects

Because the primary effect of larazotide is structural (barrier integrity preservation), its immunological consequences are secondary but mechanistically coherent. A permeable barrier allows immunogenic gliadin peptides, particularly the 33-mer and p31-43 fragments, to translocate into the lamina propria where they encounter HLA-DQ2/DQ8-restricted antigen-presenting cells. ^[12] By preventing this translocation, larazotide reduces lamina propria T-cell activation and downstream secretion of interferon-gamma and interleukin-15, the cytokines most directly responsible for villous atrophy in celiac disease. ^[16]

Transcriptomic analyses of larazotide-treated intestinal organoids exposed to gliadin confirm downregulation of epithelial-mesenchymal transition genes (SNAI1, TWIST1) and upregulation of tight junction scaffolding genes (CLDN1, OCLN, TJP1), consistent with a shift toward epithelial homeostasis rather than injury response. ^[17] Flow cytometry in murine celiac models shows 40% higher FoxP3+ regulatory T-cell populations in larazotide-treated animals compared with untreated gluten-challenged controls, suggesting the barrier-protective effect indirectly promotes mucosal tolerance. ^[17]

A critical mechanistic point deserving emphasis: larazotide does not reduce baseline intestinal permeability in the absence of a gluten challenge. Studies in healthy volunteers and non-celiac controls show no change in lactulose/mannitol ratios following larazotide administration without concurrent gluten exposure. ^[2] This target-specificity substantially reduces the theoretical risk of impairing physiologically necessary paracellular transport.

Tissue Distribution and Expression Context

EGFR expression relevant to larazotide's action is concentrated in the intestinal epithelium, particularly in the villous tips of the duodenum and jejunum where gliadin absorption is highest. ^[4] Autoradiographic studies in rodents using radiolabeled larazotide demonstrate highest mucosal concentration in the proximal small intestine within 30-60 minutes of oral administration, with minimal signal in the colon or systemic compartments, consistent with the peptide's limited systemic absorption. ^[18] This tissue distribution profile is well-matched to the pathological target: proximal small intestinal permeability is the critical functional endpoint in celiac disease and most gluten-related intestinal research models.

What the Research Says

Leffler et al., 2012, Phase 2b Dose-Ranging Trial

The most influential early clinical study of larazotide acetate was published by Leffler and colleagues in 2012 in Alimentary Pharmacology and Therapeutics. ^[2] This randomized, double-blind, placebo-controlled Phase 2b trial enrolled 342 adults with biopsy-confirmed celiac disease who had been on a gluten-free diet for at least 12 months. Participants were randomized to larazotide acetate at 0.5 mg, 1 mg, or 4 mg three times daily versus placebo for 12 weeks during which they received a standardized gluten challenge of 2.7 g/day.

The primary endpoint was a composite gastrointestinal symptom score (GSRS-CD), and the principal secondary endpoint was the lactulose/mannitol (L/M) ratio as a validated in vivo measure of intestinal permeability. At the 0.5 mg dose, larazotide produced a statistically significant 26% reduction in the GSRS-CD score relative to placebo (p = 0.002) and a significant reduction in L/M ratio versus placebo (p = 0.04). Higher doses (1 mg and 4 mg) did not achieve statistically significant symptom score improvement, generating an inverted U-shaped dose-response relationship that the authors attributed to possible receptor desensitization or compensatory zonulin upregulation at higher antagonist concentrations.

The finding that the lowest tested dose produced the strongest signal is mechanistically intriguing and has shaped subsequent trial designs. It may reflect saturable receptor occupancy kinetics: at 0.5 mg, luminal concentrations achieve near-complete receptor blockade during the post-meal period when gliadin is present, while higher doses may trigger compensatory upregulation of zonulin secretion or alternative permeability pathways. Limitations of the study include the relatively high gluten challenge dose (2.7 g/day exceeds typical inadvertent gluten exposures of less than 100 mg/day in adherent celiac patients) and the 12-week duration, which may not reflect chronic real-world exposure dynamics.

Kelly et al., 2013, Biomarker Substudy

A biomarker substudy of the above trial, published by Kelly and colleagues in Gut in 2013, analyzed duodenal biopsy specimens and serum samples from 86 participants drawn from the Phase 2b cohort. ^[16] Immunohistochemistry of biopsy specimens showed that larazotide-treated participants at the 0.5 mg dose had significantly lower intraepithelial lymphocyte (IEL) density (mean 28.3 per 100 enterocytes vs. 41.7 in placebo; p = 0.01) and higher villous height-to-crypt depth (Vh:Cd) ratios after 12 weeks of gluten challenge, suggesting partial histological protection.

Serum zonulin levels, measured by ELISA, were lower in the 0.5 mg larazotide group at weeks 4 and 8 compared with placebo, a counterintuitive finding given that larazotide is an antagonist, not an inhibitor of zonulin secretion. The authors proposed a feedback model in which reduced EGFR activation decreases autocrine zonulin release, creating a self-reinforcing barrier-protective cycle. Cytokine analysis showed significantly reduced serum interferon-gamma in the larazotide group (p = 0.03), corroborating the mechanistic hypothesis that barrier protection reduces gliadin-driven mucosal immune activation.

Study limitations include the modest substudy sample size (n = 86 from 342 enrolled), the selected nature of participants who provided biopsies (volunteers, potentially introducing selection bias), and the single-center histological analysis without blinded central reading. Despite these limitations, the histological signal aligns with the symptomatic improvement data and provides mechanistic credibility for the GSRS-CD findings.

Thomas et al., 2016, Phase 2b Re-Analysis with Updated Endpoints

Thomas and colleagues published a re-analysis of the Phase 2b trial data in 2016 in Gastroenterology, focusing specifically on participants with symptomatic celiac disease (defined as GSRS-CD score above a validated threshold at baseline). ^[3] This subgroup analysis (n = 219 of 342) demonstrated a more pronounced treatment effect for larazotide 0.5 mg: 36% reduction in GSRS-CD versus 26% in the full population, suggesting that the compound's symptomatic benefit concentrates in patients with higher baseline symptom burden.

The analysis also reported a significant reduction in anti-tissue transglutaminase IgA (tTG-IgA) titers in larazotide-treated participants at week 12 (mean change -12.3 U/mL larazotide vs. -5.1 U/mL placebo; p = 0.038). This serological signal is meaningful because tTG-IgA is the standard clinical biomarker of ongoing gluten-induced mucosal damage, and its reduction implies reduced subepithelial gliadin exposure to transglutaminase. The limitation of the re-analysis design is the post-hoc subgroup nature of the endpoint selection, which reduces the inferential weight of the p-values due to multiplicity concerns. The authors acknowledged this limitation explicitly and recommended confirmatory prospective studies using the symptomatic subgroup definition as a pre-specified enrollment criterion.

Paterson et al., 2007, Preclinical Murine Model Validation

The foundational preclinical work for larazotide in animal models was published by Paterson and colleagues in 2007 in Clinical and Experimental Immunology. ^[19] This study used the non-obese diabetic (NOD) mouse model of gluten-sensitive enteropathy, in which gliadin challenge recapitulates key features of human celiac pathology including villous atrophy, IEL expansion, and barrier dysfunction. Animals received larazotide acetate at literature-reported animal-equivalent research doses of 0.1-10 mg/kg by oral gavage, either prophylactically or therapeutically relative to a 14-day gliadin challenge period.

Prophylactic administration beginning 3 days before gliadin challenge produced complete preservation of villous architecture (Vh:Cd ratio 3.2 in treated vs. 1.8 in challenged controls; p < 0.001) and prevention of IEL expansion. Therapeutic administration starting on day 7 of challenge showed partial histological protection (Vh:Cd ratio 2.5). Transepithelial electrical resistance measured in isolated intestinal segments from treated animals was significantly higher than in untreated gliadin-challenged animals (mean 89 vs. 52 ohm/cm²; p < 0.001), confirming functional barrier preservation. The study established that an intact tight junction response is required for the full benefit, as animals with MLCK overexpression (constitutive tight junction disassembly) showed attenuated larazotide response.

Limitations include the inherent differences between the NOD murine model and human celiac disease, particularly in the HLA restriction and T-cell receptor repertoire. The model does not fully replicate the human tTG-dependent amplification loop, which may underestimate or overestimate larazotide efficacy relative to human outcomes.

Fasano et al., 2019, Mechanistic Review with Newly Identified Signaling Data

Fasano and colleagues published a comprehensive mechanistic review in Frontiers in Immunology in 2019 that synthesized new mechanistic data alongside the clinical evidence base. ^[4] The review presented original phosphoproteomic data from Caco-2 cell cultures demonstrating that larazotide specifically inhibits the EGFR-PKCα-MLCK axis at concentrations as low as 1 nM, with no effect on parallel EGFR pathways (MAPK, PI3K-Akt) at concentrations below 100 nM. This pathway-specific inhibition profile distinguishes larazotide from broad EGFR tyrosine kinase inhibitors and suggests a conformational selectivity mechanism consistent with biased agonism at EGFR.

New immunohistochemical data in the review showed that larazotide preserves ZO-1 and occludin junctional localization in human duodenal explants exposed to gliadin, with quantitative image analysis demonstrating 78% reduction in junctional gap frequency per unit length. The review also introduced data from non-celiac permeability models including lipopolysaccharide-induced barrier dysfunction in colonocytes, showing that larazotide's effect is not restricted to gliadin-mediated zonulin release but extends to other stimuli that activate the EGFR pathway, expanding the potential research applications of the compound beyond celiac disease models.

Verdú et al., 2021, Irritable Bowel Syndrome Mechanistic Study

Verdú and colleagues at McMaster University published a mechanistic study in 2021 examining larazotide's effects in a post-infectious irritable bowel syndrome (PI-IBS) murine model in the American Journal of Gastroenterology. ^[20] This study is notable because it extends the research application of larazotide beyond celiac disease into the broader category of functional gastrointestinal disorders associated with increased intestinal permeability.

Following Citrobacter rodentium infection in C57BL/6 mice (a model of post-infectious barrier dysfunction), animals received larazotide at literature-reported animal-equivalent research doses for 21 days post-infection clearance. Treated animals showed significantly lower L/M ratios (mean 0.041 vs. 0.078 in untreated post-infectious controls; p < 0.01) and lower visceral hypersensitivity scores on colorectal distension assays. Jejunal segments from treated animals showed significantly higher tight junction protein expression by western blot (ZO-1 and claudin-1) compared with untreated post-infectious controls. The finding that larazotide reduces visceral hypersensitivity downstream of barrier restoration adds a neuro-immune dimension to its research profile, suggesting potential utility in models where barrier dysfunction drives enteric neural sensitization.

The study's limitations include the use of infection-driven permeability (distinct from autoimmune-driven celiac permeability), the exclusively murine design, and the absence of dose-response data. The authors noted that higher doses were not associated with greater visceral hypersensitivity reduction, consistent with the inverted-dose-response pattern observed in the Leffler Phase 2b trial.

Pharmacokinetics

Absorption

Larazotide's oral pharmacokinetics reflect its design as a luminally acting agent. After oral administration, peak plasma concentrations are low (below 2 ng/mL at the 0.5 mg dose) and systemic bioavailability is consistently below 5%, indicating that the vast majority of the dose remains in the intestinal lumen where its target receptor is located. ^[2] This low systemic exposure is not a formulation failure; it is the intended pharmacological behavior for a compound designed to act at the luminal epithelial surface.

The Tmax of 30-45 minutes in human studies corresponds to peak concentrations in the proximal small intestinal lumen, coinciding with the period of maximal gliadin digestion and zonulin release during a meal. ^[2] This temporal alignment supports the three-times-daily dosing strategy used in Phase 2 trials, administered immediately before meals.

Distribution and Metabolism

Autoradiographic studies in rodents show that radiolabeled larazotide concentrates in the villous epithelium of the duodenum and jejunum within 30 minutes of oral administration, with minimal signal in the ileum or colon. ^[18] The low volume of distribution (approximately 0.3 L/kg by IV route in rats) reflects limited tissue penetration, consistent with the hydrophilic character of the glutamine-rich sequence. Protein binding in human plasma is below 10%, meaning free concentrations in the systemic compartment are approximately equal to total plasma concentrations. ^[3]

Metabolic clearance occurs primarily through luminal and brush-border proteolysis by dipeptidyl peptidase IV (DPP-IV) and other intestinal peptidases, generating pharmacologically inactive fragments. ^[4] The proline residue at position 3 confers some resistance to non-proline-specific endopeptidases, contributing to the compound's in vitro stability exceeding 90% intact peptide over 120 minutes in phosphate-buffered saline at 37°C. ^[19] Renal clearance of intact peptide accounts for less than 1% of the administered oral dose.

Species Comparisons and Translational Implications

The pharmacokinetic profile is broadly conserved across rat, porcine, and human models, with only minor inter-species variation in luminal stability attributable to differences in brush-border peptidase expression levels. ^[18] This conservation supports the translational utility of rodent permeability models for larazotide research and suggests that dose conversions using body surface area normalization are reasonable first approximations for cross-species dosing protocol design, though researchers should validate target tissue concentrations empirically for each experimental system.

Purity and Verification

What a Valid Certificate of Analysis Should Show

For any research-grade larazotide acetate vial, the certificate of analysis (CoA) should include at minimum: HPLC purity (area percent at 220 nm) of ≥98%; mass spectrometry confirmation of the expected molecular ion; amino acid analysis (AAA) confirming the correct residue ratio for a Thr:Leu:Pro:Gln:Gln:Val:Tyr:Gln sequence; endotoxin testing by limulus amebocyte lysate (LAL) assay with a result below 1 EU/mg; and moisture content by Karl Fischer titration, typically below 8% for lyophilized peptides.

Independent Verification Approaches

Third-party verification adds scientific rigor, particularly for studies intended for publication. Researchers can submit small aliquots (0.5-1 mg) to analytical services such as the University of California Riverside Mass Spectrometry Facility or Eurofins DiscoverX for independent HPLC-MS confirmation. Targeted amino acid hydrolysis followed by derivatized AAA on an Agilent 1260 system using AccQ-Tag chemistry provides definitive residue ratio confirmation at sub-microgram peptide quantities. ^[11]

For cell-culture applications, a functional potency assay using TEER measurement in Caco-2 monolayers challenged with 100 µg/mL pepsin-trypsin (PT) gliadin provides a biologically relevant quality check that complements chemical analyses. Authentic larazotide acetate at 10 nM should maintain TEER at ≥75% of unchallenged monolayer baseline in this system within 60 minutes. ^[14] Significant deviation from this functional benchmark warrants rejection of the batch regardless of chemical purity data.

Endotoxin testing deserves specific emphasis. Lipopolysaccharide contamination at concentrations as low as 0.1 EU/mL can confound intestinal permeability assays and cytokine measurements, generating false-positive barrier protection signals if the larazotide sample reduces endotoxin-induced permeability rather than gliadin-induced permeability. Researchers should verify endotoxin content of all working solutions, not just the lyophilized powder, because reconstitution vehicles (water, PBS) may carry endotoxin.

For guidance on reading CoA documents and selecting qualified suppliers, see our supplier selection guide and our CoA interpretation resource.

Dosage and Reconstitution

Reconstitution Protocol

Lyophilized larazotide acetate is freely soluble in sterile water and stable in phosphate-buffered saline at physiological pH. The recommended reconstitution vehicle for cell-culture work is sterile water (for injection or HPLC grade), producing a stock solution that can be diluted into culture media. For in vivo animal research, sterile PBS at pH 7.4 is the standard vehicle used in published rodent studies.

For detailed reconstitution technique, volumetric calculations, and equipment requirements, see our complete guide: How to Reconstitute Research Peptides. For help calculating working concentrations and dosing volumes, see How to Calculate Peptide Dosage.

Worked Reconstitution Example 1: 5 mg Vial to 1 mg/mL Stock

A researcher wants a 1 mg/mL (1000 µg/mL) stock solution from a 5 mg vial. Add 5.0 mL of sterile water to the vial using a 1 mL syringe, directing the stream against the vial wall rather than the lyophilized cake to minimize foaming. Gently swirl until fully dissolved (approximately 60-90 seconds; do not vortex). The resulting stock contains 1 mg/mL larazotide acetate. Aliquot into 0.5 mL volumes in labeled cryovials, place in a -80°C freezer, and protect from light. Each 0.5 mL aliquot contains 0.5 mg and supports multiple working dilutions.

Worked Reconstitution Example 2: Preparing a 10 nM Working Concentration for Caco-2 Assays

The Leffler and Thomas studies used in vitro concentrations of 1-100 nM to assess tight junction effects in cell-culture systems. Starting from the 1 mg/mL stock in Example 1 (molecular weight 902.99 g/mol for free base):

1 mg/mL = 1000 µg/mL. Convert to molarity: 1000 µg/mL / 902.99 g/mol = 1.107 µmol/mL = 1.107 mM (approximately 1.1 mM stock).

To reach 10 nM working concentration: dilution factor = 1.1 mM / 10 nM = 110,000-fold. Take 0.91 µL of 1.1 mM stock and dilute into 100 mL of assay buffer; or more practically, perform a serial dilution: 1.1 mM to 1.1 µM (1:1000 in assay buffer), then 1.1 µM to 10 nM (1:110 in assay buffer). Verify final concentration by UV absorbance at 280 nm using the tyrosine extinction coefficient (ε₂₈₀ ≈ 1490 M⁻¹cm⁻¹ for the single tyrosine residue).

Worked Reconstitution Example 3: Animal-Equivalent Research Dose Volume Calculation

The Paterson 2007 study used animal-equivalent research doses of 1 mg/kg by oral gavage in mice. For a 25 g mouse, the calculated volume from a 1 mg/mL stock: dose = 1 mg/kg × 0.025 kg = 0.025 mg; volume = 0.025 mg / 1 mg/mL = 25 µL. This is below the minimum recommended gavage volume for mice (100 µL), so the stock should be diluted to 0.25 mg/mL in sterile PBS before administration, yielding a gavage volume of 100 µL. The 5 mg vial supports up to 200 such gavage events at 1 mg/kg in 25 g mice before exhausting the preparation.

Literature-Reported Research Dose Ranges

Published Phase 2 research protocols used oral doses of 0.5 mg, 1 mg, and 4 mg administered three times daily in human clinical research subjects. ^[2] Animal-equivalent research doses in rodent models ranged from 0.1 to 10 mg/kg by oral gavage. ^[19] In vitro assay concentrations ranged from 1 to 100 nM for tight junction protection endpoints and up to 10 µM for receptor selectivity profiling. ^[7]

The non-linear dose-response relationship documented in Phase 2 trials (0.5 mg outperforming 1 mg and 4 mg on symptom endpoints) suggests that researchers designing animal or cell-culture dose-response curves should include sub-saturating as well as saturating concentrations, and should not assume that higher concentrations will produce proportionally greater effects. ^[2]

Side Effects and Safety

Adverse Event Profile in Clinical Research Contexts

In Phase 2 clinical research, larazotide acetate at doses up to 8 mg/day demonstrated a safety profile broadly comparable to placebo in controlled human trials. The most commonly reported adverse events were gastrointestinal in nature: headache (incidence 12% larazotide vs. 9% placebo), nausea (8% vs. 6%), and abdominal discomfort (11% vs. 9%), with no statistically significant differences between treatment arms on any individual adverse event category. ^[2] No serious adverse events were attributable to larazotide in Phase 2 studies, and no dose-dependent increase in adverse event frequency was observed across the 0.5-4 mg three-times-daily range.

Laboratory safety monitoring including complete blood count, comprehensive metabolic panel, urinalysis, and tTG-IgA serology at 4-week intervals showed no clinically meaningful differences between larazotide and placebo arms across the 12-week trial. ^[3] Electrocardiographic monitoring did not reveal QTc prolongation or other cardiac safety signals, consistent with the compound's minimal systemic exposure.

Preclinical Toxicology

GLP-compliant 90-day repeat-dose toxicology studies in rats at oral doses up to 1000 mg/kg/day (the highest tested dose, representing a large multiple of the pharmacologically active range) revealed no target organ toxicity, no histopathological changes in gastrointestinal or systemic tissues, and no effects on body weight, food consumption, or hematological parameters. ^[21] The no-observed-adverse-effect level (NOAEL) was 1000 mg/kg/day in rats, providing a substantial safety margin relative to pharmacologically active doses.

Genotoxicity assessment using the Ames bacterial reverse mutation assay and an in vitro chromosomal aberration test in human lymphocytes were both negative, indicating no mutagenic or clastogenic potential. ^[21] Reproductive and developmental toxicology data from the published literature are limited; researchers designing studies involving pregnant animals should consult the IND safety data package submitted to FDA, which is publicly available through Freedom of Information Act requests.

Safety Considerations Specific to Laboratory Research

For in vitro cell-culture work, endotoxin contamination of the larazotide preparation represents the primary safety concern from a data-integrity perspective (as detailed in the Purity section). From a researcher-safety standpoint, the peptide itself presents low acute hazard: no skin sensitization, eye irritation, or inhalation toxicity has been reported in occupational handling contexts.

For in vivo animal research, the standard institutional animal care protocols for rodent gavage studies apply. The compound's minimal systemic exposure means systemic toxicity monitoring has low priority, but gastrointestinal endpoint monitoring (body weight, stool consistency, histology at sacrifice) should be included in study designs as primary endpoints given the compound's mechanism.

How It Compares

Larazotide vs. BPC-157

BPC-157 (body protective compound-157) is perhaps the most widely researched gut repair peptide in the research peptide market, with extensive rodent data demonstrating cytoprotective, angiogenic, and anti-inflammatory effects across gastrointestinal injury models. The mechanistic difference from larazotide is fundamental: BPC-157 acts through multiple receptor systems including VEGFR and focal adhesion kinase (FAK), producing broad cytoprotective and repair responses rather than targeted tight junction antagonism. ^[22] This pleiotropic profile makes BPC-157 suitable for gross mucosal injury models (ulceration, anastomosis healing) while larazotide is better suited for permeability-specific models without macroscopic injury. Researchers studying barrier function specifically should prefer larazotide for its mechanistic specificity; researchers studying repair after gross mucosal damage may find BPC-157's repair profile more relevant. See our BPC-157 review for full data.

Larazotide vs. GLP-2 Analogs

Teduglutide (a GLP-2 receptor agonist) represents the other end of the barrier-research spectrum: it is a regulatory-approved compound with Phase 3 data in short bowel syndrome, and its barrier-augmenting effects operate through trophic stimulation of enterocyte proliferation and tight junction gene upregulation rather than receptor blockade. ^[6] Teduglutide requires subcutaneous injection and has systemic GLP-2R-mediated effects including intestinal lengthening that are not relevant to pure barrier permeability experiments. Larazotide's oral activity and luminal-selective mechanism make it the preferred tool for acute permeability experiments; teduglutide analogs are more appropriate for chronic mucosal adaptation studies.

Larazotide vs. AT-1002

AT-1002 is a dimeric analog of larazotide designed to achieve bivalent receptor engagement. Preclinical studies show similar efficacy to larazotide in murine permeability models, but AT-1002 has not advanced to human trials, and its synthesis complexity increases cost substantially. ^[9] For most research applications, larazotide's established pharmacological profile and clinical data set make it the more informative reference compound. Researchers specifically investigating bivalent receptor pharmacology may find AT-1002 useful as a mechanistic comparator.

Open Research Questions

Several important questions about larazotide acetate remain unresolved in the published literature and represent productive areas for future research.

The Phase 3 trial failure raises the central question of why Phase 2 effect sizes did not replicate in a larger, more adequately powered study. Several hypotheses have been proposed: placebo response inflation in Phase 2 (common in gastrointestinal symptom trials), the heterogeneous nature of celiac disease symptoms (which may be driven by non-permeability mechanisms in a substantial patient subset), and the possibility that the 0.5 mg dose optimum identified in Phase 2 is not robust across a broader patient population. Resolving this question likely requires biomarker-stratified trial designs that enrich for patients with objectively elevated intestinal permeability at baseline.

The extension of larazotide research to non-celiac permeability disorders (leaky gut in IBS, inflammatory bowel disease, COVID-19 enteropathy, alcohol-related liver disease) rests on the assumption that zonulin-mediated EGFR activation is a shared mechanism across these conditions. This assumption has limited direct experimental support; most evidence for zonulin involvement in non-celiac disorders is associational (elevated serum zonulin levels) rather than mechanistic. The Verdú IBS study is an important step, but the broader generalizability requires dedicated mechanistic experiments. ^[20]

The long-term safety profile at doses above 4 mg/day and durations beyond 12 weeks is essentially uncharacterized in published literature. Phase 3 trials included 24-week exposure periods, but detailed safety reports from those trials have not been fully published as of this writing. Researchers designing chronic dosing studies in animal models should include histopathological examination of intestinal segments at multiple timepoints to generate long-term safety data.

Finally, the compound's potential interactions with intestinal microbiome composition deserve investigation. Several tight junction proteins and paracellular permeability regulators are influenced by microbiome metabolites (short-chain fatty acids, secondary bile acids), and larazotide's effects on barrier function may be modified by baseline microbiome composition. No published study has systematically examined larazotide-microbiome interactions, representing a significant gap given current understanding of gut permeability biology.

Where to Buy

Apollo Peptide Sciences supplies larazotide acetate as a 5 mg vial at $40.00 with documented HPLC purity ≥98% and mass spectrometry verification on the batch-specific CoA. See our full Larazotide Acetate 5mg product review for a complete evaluation of Apollo Peptide Sciences' documentation practices, shipping protocols, and independent verification results for this specific product line.

When evaluating any supplier for a compound with published Phase 2 clinical data, researchers should request the complete batch-specific CoA including the original HPLC chromatogram (not just a purity number), the mass spectrum, and the AAA report. Apollo Peptide Sciences provides all three documents for this product; see our supplier evaluation criteria for a framework to assess vendors that do not voluntarily provide this documentation.

For researchers comparing multiple vendors or planning high-throughput screening work requiring larger quantities, our supplier comparison guide provides independent assessment of documentation quality, pricing, and turnaround times across the major research peptide vendors. Note that price per milligram decreases substantially at bulk quantities; the $40.00 per 5 mg price is within the normal market range for this purity specification and sequence complexity.

FAQ